Compare ANPA & TCRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ANPA | TCRX |
|---|---|---|
| Founded | 2016 | 2018 |
| Country | Hong Kong | United States |
| Employees | 32 | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 47.0M | 49.4M |
| IPO Year | 2024 | 2021 |
| Metric | ANPA | TCRX |
|---|---|---|
| Price | $2.62 | $0.32 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 49.0K | ★ 935.8K |
| Earning Date | 02-06-2026 | 05-08-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 12.28 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $10,325,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.81 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 266.65 |
| 52 Week Low | $2.81 | $0.33 |
| 52 Week High | $180.64 | $2.57 |
| Indicator | ANPA | TCRX |
|---|---|---|
| Relative Strength Index (RSI) | 27.32 | 17.58 |
| Support Level | N/A | N/A |
| Resistance Level | $4.59 | $0.82 |
| Average True Range (ATR) | 0.34 | 0.05 |
| MACD | -0.12 | -0.04 |
| Stochastic Oscillator | 2.41 | 1.88 |
Rich Sparkle Holdings Ltd is a holding company conducting its operations as a professional specialist in the provision of financial printing services such as printing, typesetting and translation, advisory services including Environmental, Social and Governance (ESG) and internal control reporting services and other services including standalone annual general meeting and extraordinary general meeting supporting service and other standalone services, through its sole operating subsidiary in Hong Kong. Its segments include Financial printing services such as printing, typesetting and translation, Advisory services including Environmental, Social and Governance Report and Other services.
TScan Therapeutics Inc is a fully integrated clinical-stage biotechnology company focused on developing a robust pipeline of T cell receptor (TCR)-engineered T cell, or TCR-T, therapies for the treatment of patients with cancer. The company's liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. It is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.